Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria
Phase 3positivetabirafusp-tedZenkudaPositive
AI Analysis
Summary
Kodiak Sciences announced that Zenkuda (tabirafusp-ted) met primary endpoints in the pivotal Phase 3 DAYBREAK trial for wet age-related macular degeneration, demonstrating sustained clinical effect with a majority of patients requiring dosing every 24 weeks.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoints in pivotal DAYBREAK trial with strong immediacy and sustained clinical effect; majority of patients on 24-week dosing interval
Importance:8/10
Sentiment:
0.95
retinaophthalmologywAMDPhase 3positive datapivotal trial
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 28, 2026 4:09 AM